Validated across a wide range of peer-reviewed publications

We work with forward-looking researchers to demonstrate the clinical value of our solutions to patients, clinicians and the risk-bearing payors such as health plans and accountable care organizations (ACOs) that support them.

Clinical Evidence

AstraZeneca real-world evidence study for a severe asthma treatment uses NuvoAir to monitor and assess lung function

NuvoAir resulted in high adherence, high reliability and high concordance with hospital-based spirometry in Boston Children's Hospital study

COPD members are highly engaged when supported by care coordinators in NuvoAir Virtual-First Care

Regeneron observational study used NuvoAir to monitor effects of allergen exposure on asthma patients

NuvoAir Cough app shows precision rate of 84% in detecting coughs

Improved clinical outcomes seen with long-term use of the NuvoAir Home platform

Patients and clinicians in England-wide survey report high value and trust with NuvoAir Home to detect changes in lung function and monitor lung health

Improved attendance rates and reduced hospital admission rates with virtual clinics supported by NuvoAir Home for patients with difficult asthma

Adults with severe asthma perform high quality unsupervised home spirometry with NuvoAir

High acceptability of NuvoAir home monitoring with pediatric asthma patients at Royal Brompton Hospital

Quality and high adherence to NuvoAir Home shows promise for long-term monitoring of pediatric asthma

NuvoAir supports home administration of biologics for pediatric severe asthma

NuvoAir Home respiratory platform supports remote monitoring of asthma patients

Unsupervised home spirometry with the platform is found equivalent to in-clinic spirometry

NuvoAir with unsupervised in-app coaching meets ATS/ERS repeatability criteria for both pediatric CF and bronchiectasis patients

Swedish pilot shows technology can be used at home by children with CF with postive experience of virtual clinics

Proven effective in driving virtual consultations during an 18-month patient research

Pilot Study with Göteborg, Respiratory Medicine confirms NuvoAir Platform well complements CF care

NuvoAir Reduced Booked and Urgent Face to Face Consultations in Cystic Fibrosis Patients

Pilot study with Royal Brompton Hospital suggests NuvoAir platform may improve Cystic Fibrosis outcomes

Validation of the Technology

Pediatric asthma and cystic fibrosis study validates NuvoAir spirometer against conventional spirometry

Validation of Air Next spirometer in patients with different respiratory diseases

NuvoAir supports 10,000 Families Study for health assessment screening in Minnesota, U.S.

Air Next supports Kazakhstan Academy of Preventive Medicine in assessing lung function changes in a COPD patient population

200 patient study validates Air Next against Gold standard spirometry

NuvoAir technology chosen for lung function monitoring in ALS study

NuvoAir technology supports 26 300 COPD patient study in Germany

200 patient study at Tygerberg Academic Hospital, Cape Town, South Africa validates NuvoAir spirometry technology

200 patient study at University Hospital Complex of Vigo, Spain validates NuvoAir spirometry technology

Real-World-Data from our engagements reveals great health economic outcome potential and staggering acceptance

9.4 - Acceptance of NuvoAir solution on a scale from 0 to 10

Booked
Consultations

Urgent
Consultations

Improved understanding
of their condition

Improved
medication adherence

ePS1.07 Patient experience of virtual consultations: survey results, Journal of Cystic Fibrosis Volume 19, Supplement 2, June 2020, Page s39

Our Partners

Hospitals, universities, pharma companies and CROs around the world have chosen NuvoAir as their respiratory partner. We’re proud to support the work of forward-thinking, innovative players and researchers.